Danske Bank’s BridgeBio Pharma BBIO Stock Holding History

Danske Bank’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.9K	Hold	200	–	–	﹤0.01%	769
2026 Q1	$14.9K	Sell	200 -1,800	-90%	-$130K	﹤0.01%	759
2025 Q4	$153K	Hold	2,000	–	–	﹤0.01%	702
2025 Q3	$104K	Hold	2,000	–	–	﹤0.01%	855
2025 Q2	$86.4K	Buy	+2,000	New	+$72.7K	﹤0.01%	886

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Danske Bank's BBIO Position: Q2 2026 in Review

Danske Bank held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 200 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Danske Bank first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $153K in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Danske Bank held 200 shares of BridgeBio Pharma worth $14.9K as of Q2 2026.
Danske Bank left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #769 holding.
Danske Bank first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
Danske Bank's BridgeBio Pharma position peaked at $153K in Q4 2025.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.